Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.

MLA

A V Ramanan, et al. “Defining Consensus Opinion to Develop Randomised Controlled Trials in Rare Diseases Using Bayesian Design: An Example of a Proposed Trial of Adalimumab versus Pamidronate for Children with CNO/CRMO.” PLoS ONE, vol. 14, no. 6, Jan. 2019, p. e0215739. EBSCOhost, https://doi.org/10.1371/journal.pone.0215739.

APA

A V Ramanan, L V Hampson, H Lythgoe, A P Jones, B Hardwick, H Hind, B Jacobs, D Vasileiou, I Wadsworth, N Ambrose, J Davidson, P J Ferguson, T Herlin, A Kavirayani, O G Killeen, S Compeyrot-Lacassagne, R M Laxer, M Roderick, J F Swart, … M W Beresford. (2019). Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO. PLoS ONE, 14(6), e0215739. https://doi.org/10.1371/journal.pone.0215739

Chicago

A V Ramanan, L V Hampson, H Lythgoe, A P Jones, B Hardwick, H Hind, B Jacobs, et al. 2019. “Defining Consensus Opinion to Develop Randomised Controlled Trials in Rare Diseases Using Bayesian Design: An Example of a Proposed Trial of Adalimumab versus Pamidronate for Children with CNO/CRMO.” PLoS ONE 14 (6): e0215739. doi:10.1371/journal.pone.0215739.